Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members

CNBC's Jim Cramer on Monday emphasized his belief that companies making GLP-1 diabetes and obesity drugs will be valuable.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.